Clinical Trial Update: Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reporting efficacy and safety of PT001 vs placebo and open-label Spiriva in subjects with persistent asthma across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• PT001
• SPIRIVA RESPIMAT (tiotropium bromide inhalation spray)

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: Asthma | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-08-12